Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Evolus

< Previous 1 2 3 4 Next >
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Third Quarter 2024 Results
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in Stifel 2024 Healthcare Conference
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Third Quarter Financial Results on November 6, 2024
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Hold Investor Day on September 12, 2024
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Second Quarter Financial Results on July 31, 2024
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Appointment of Albert G. White III to Board of Directors
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
From Evolus
Via Business Wire
Tickers EOLS
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
From Evolus
Via Business Wire
Tickers EOLS
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports First Quarter 2024 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report First Quarter Financial Results on May 7, 2024
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
From Evolus
Via Business Wire
Tickers EOLS
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.